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Polyunsaturated fatty acidOxidative damage to vascular cell membrane phospholipids causes physicochemical changes in membrane
structure and lipid organization, contributing to atherogenesis. Oxidative stress combined with
hyperglycemia has been shown to further increase the risk of vascular and metabolic diseases. In this
study, the effects of glucose on oxidative stress-induced cholesterol domain formation were tested in model
membranes containing polyunsaturated fatty acids and physiologic levels of cholesterol. Membrane
structural changes, including cholesterol domain formation, were characterized by small angle X-ray
scattering (SAXS) analysis and correlated with spectrophotometrically-determined lipid hydroperoxide
levels. Glucose treatment resulted in a concentration-dependent increase in lipid hydroperoxide formation,
which correlated with the formation of highly-ordered cholesterol crystalline domains (unit cell periodicity
of 34 Å) as well as a decrease in overall membrane bilayer width. The effect of glucose on lipid peroxidation
was further enhanced by increased levels of cholesterol. Treatment with free radical-scavenging agents
inhibited the biochemical and structural effects of glucose, even at elevated cholesterol levels. These data
demonstrate that glucose promotes changes in membrane organization, including cholesterol crystal
formation, through lipid peroxidation.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Oxidative modiﬁcation of membrane lipids contributes to the
pathophysiology of cardiovascular disease and associated risk
factors such as diabetes, dyslipidemia and hypertension [1,2].
Insulin resistance and poor glycemic control are directly associated
with mechanisms of atherosclerosis by various chemical pathways,
including non-enzymatic glucose reactions [3,4]. Several studies of
glucose autoxidation focus primarily on the biochemical effects of
the glycation products generated from the Maillard reaction of
glucose with amine groups on proteins and lipids [5,6]. Although
the biochemical and physiological effects of these glycation
products have been studied extensively [7,8], there has been less
attention paid to the biophysical effects of glucose-induced
oxidative damage to non-amine membrane lipids [9,10]. The effect
of glucose on polyunsaturated fatty acids (PUFA) and cholesterol is
especially important since alterations of these lipids have been
shown to promote vascular disease and insulin resistance [11,12].
Oxidation of low-density lipoproteins (LDL), in particular, contri-
butes to atherosclerotic foam cell formation in the arterial wall
[13]. In addition, peroxidation of plasma membrane lipids leads to1 978 921-4195.
. Self-Medlin).
ll rights reserved.the formation of cholesterol crystalline domains in vascular smooth
muscle cells, which can cause inﬂammation and plaque instability
[14,15].
In this study, we used small angle X-ray scattering (SAXS) to
examine the physicochemical effects of glucose on membrane lipid
peroxidation and structural organization in vesicles composed of
ﬁxed levels of PUFAs and cholesterol without adding exogenous
radical initiators. Pronounced changes in membrane lipid organiza-
tion were observed with glucose treatment, including the formation
of discrete cholesterol crystalline domains and a reduction in
overall membrane width. Concurrent spectrophotometric measure-
ments showed a correlation between these physical changes and an
increase in lipid hydroperoxide (LOOH) formation (an intermediate
product of oxidative lipid damage) that could be inhibited with
lipophilic agents that have antioxidant scavenger properties.
However, when compared to glucose treatment, membrane treat-
ment with the structurally similar sugar alcohol, mannitol, resulted
in signiﬁcantly less LOOH formation.
2. Materials and methods
2.1. Materials
1,2-Dilinoleoyl-sn-glycero-3-phosphocholine (DLPC) and 1,2-
diarachidonoyl-sn-glycero-3-phosphocholine (DAPC) dissolved in
1399Y. Self-Medlin et al. / Biochimica et Biophysica Acta 1788 (2009) 1398–1403HPLC grade chloroform were purchased from Avanti Polar Lipids
(Alabaster, AL) in sealed ampules and stored at −80 °C. Powder
cholesterol was also purchased from Avanti Polar Lipids and the
prepared stock solution in HPLC grade chloroform was stored at
−20 °C. Atorvastatin o-hydroxy metabolite (ATM) and amlodipine
besylate (AML) were provided by Pﬁzer, Inc (Groton, CT) and
500 μM stock solutions were prepared in ethanol. Other chemicals
were purchased from VWR (West Chester, PA) or Sigma-Aldrich
(Saint Louis, MO). 100 mM glucose and mannitol solutions were
prepared in diffraction buffer (0.5 mM HEPES, 154 mM NaCl, pH
7.3) and diluted with additional buffer to achieve the desired
sample concentrations. CHOD-iodide colorimetric reagent was
prepared, with modiﬁcations, from El-Saadani's method [16] and
consisted of 200 mM K2HPO4, 120 mM KI, 0.15 mM NaN3,
0.01 mM ammonium molybdate and 0.278 mM benzalkonium
chloride. At the beginning of each experiment, 24 μM disodium
ethylenediaminetetraacetic acid (EDTA) and 20 μM butylated
hydroxytoluene (BHT) were added as antioxidants to an aliquot
of CHOD-iodide reagent to halt further oxidation of samples. In
addition, 0.2% Triton X-100 detergent was added to disperse the
lipids in solution.
2.2. Multilamellar vesicle preparation for lipid peroxidation
Phospholipid (PL) and cholesterol at ﬁxed mole ratios ranging
from 0.0–0.8 cholesterol-to-phospholipid (C/P), were combined
with vehicle (ethanol) or drug in glass test tubes and shell-dried
under a stream of N2 gas while vortex mixing. Samples were then
further dried under vacuum for 1 h to remove residual solvent.
Multilamellar vesicles (MLVs) were formed by suspending the dried
lipid samples in diffraction buffer at the desired concentrations of
glucose or mannitol (0, 5, 10, 50 mM) to yield a ﬁnal PL concen-
tration of 1 mg/mL. Samples were then vortexed vigorously for
3 min at room temperature [17].
2.3. Multilamellar vesicle preparation for X-ray diffraction analysis
Phospholipid and cholesterol at 0.6 C/P were combined with
vehicle or drug and then prepared and dried as described above.
Samples were suspended in diffraction buffer or 10 mM glucose
solution to yield MLVs with a PL concentration of 2.5 mg/mL. MLVs
were formed by vortex mixing for 3 min at room temperature [17].
Immediately following initial MLV preparation and at each subsequent
24 h timepoint, aliquots of each membrane sample were taken for
SAXS and CHOD-spectrophotometric assay measurements in order to
correlate the X-ray diffraction proﬁles with the lipid hydroperoxide
concentration values.
2.4. Lipid hydroperoxide concentration measurement
MLV samples were subjected to time-dependent autoxidation by
incubating at 37 °C in an uncovered water bath. This method of
autoxidation allows lipid peroxidation to occur gradually without
the use of added initiators. Aliquots of each sample were removed at
24 h intervals and combined with 1 mL of active CHOD-iodide
reagent. The aliquots were reduced with each successive timepoint
from 100 to 10 μg of lipid to ensure that spectrophotometric
absorption readings were within the optimal range. The samples
were then covered and stored in darkness for at least 3 h. Triiodide
(I3−), formed by the oxidation of iodide (I−) by hydroperoxides, is
directly proportional to the concentration of lipid hydroperoxides
[16]. Through the CHOD colorimetric assay, the extent of peroxida-
tion was determined by measuring the absorption of I3− (molar
absorptivity coefﬁcient (ɛ) of 2.46×104 M−1 cm−1) at 365 nm in a
Beckman Coulter DU-640 spectrophotometer (Fullerton, CA). LOOH
concentration values were expressed as mean±S.D. (n=5).2.5. Preparation of samples for X-ray diffraction analysis
The effects of glucose and mannitol on membrane structure were
measured over 48 h at speciﬁc timepoints. Membrane samples were
oriented for X-ray diffraction as described previously [18]. Brieﬂy,
aliquots of MLVs containing 250 μg of phospholipid were transferred
to Lucite sedimentation cells with preloaded aluminum foil sub-
strates for collection of single membrane pellets. The sedimentation
cells contained 0.35 μM BHT to prevent further oxidation during
processing. Samples were then centrifuged in a Sorvall AH-629
swinging bucket ultracentrifuge rotor (DuPont) at 35,000 g, 5 °C.
Samples taken at the experiment initiation and at 9 and 24 h were
centrifuged for 1.5–2 h; samples analyzed beyond the 24 h period
were centrifuged for 20 h. Following centrifugation, the supernatant
was removed and the aluminum foil substrate, supporting the
oriented membrane pellet, was mounted onto a curved glass slide.
The samples were placed into either hermetically sealed brass
diffraction canisters for analysis or glass vials for storage, which
contained potassium tartrate (K2C4H4O6·1/2 H2O) to establish a 74%
relative humidity (RH) level; samples were incubated at this RH and
20 °C for at least 1 h prior to and during X-ray diffraction.
2.6. Small angle X-ray diffraction analysis
A description of SAXS theory and data analysis has been described
previously [19]. Brieﬂy, X-ray diffraction experiments were conducted
by aligning the curved substrates supporting the membrane samples
at grazing incidence with respect to a collimated, monochromatic
CuKα X-ray beam (Kα1 and K α2 unresolved; λ=1.54 Å) produced by a
Rigaku Rotaﬂex RU-200, high-brilliance microfocus generator
(Rigaku-MSC, The Woodlands, TX). Diffraction data were collected
on a one-dimensional, position-sensitive electron detector (Hecus X-
ray Systems, Graz, Austria) located 150 mm from the sample. A
measurement of crystalline cholesterol monohydrate was used to
verify the detector calibration. The unit cell periodicity (d-space) of
the membrane lipid bilayer was calculated as deﬁned by Bragg's Law.
2.7. Statistical analysis
Peroxidation data are presented as mean±S.D. Statistical diffe-
rences between results from independent experimental conditions
were tested using the two-tailed unpaired Student's t-test or one-
way analysis of variance with the Dunnett multiple comparisons test.
A value of pb0.05 was considered signiﬁcant.
3. Results
3.1. Effect of glucose on lipid peroxidation
We measured the dose-dependent effects of glucose on LOOH
formation in lipid vesicles composed of phospholipid with ﬁxed
amounts of PUFAs and cholesterol. The addition of 5, 10 and 50 mM
glucose to the DLPC membrane vesicles at 0.6 C/P caused a signiﬁcant
and concentration-dependent increase in peroxidation relative to
control (Fig. 1). Similar effects of glucose were observed in DAPC
membrane vesicles at 0.2 C/P (data not shown).We alsomeasured the
lipid peroxidation effects of mannitol, a non-reducing sugar alcohol
commonly used as a control in comparison with glucose for in vivo
studies [13,20]. As shown in Fig. 1, glucose signiﬁcantly ampliﬁed lipid
peroxidation compared to mannitol at equivalent concentrations.
The membrane cholesterol content can also affect the efﬁciency of
free radical propagation through a lipid bilayer by altering the physical
packing of the phospholipids [15]. To examine the inﬂuence of glucose
on this effect, we measured LOOH formation in DLPC membranes
prepared with a range of C/P mole ratios in the absence (control) or
presence of 50 mM glucose. The control samples showed no signi-
Fig. 2. Glucose accelerated cholesterol-dependent effects on LOOH formation in model
membranes. DLPC membranes were incubated at 37 °C for 48 h in the presence or
absence of 50 mM glucose at incremental C/P ratios. Total levels of LOOH were
measured by the CHOD-iodide assay and the percent increase in LOOH was determined
from comparison to untreated controls at same C/P ratio. ⁎pb0.001 glucose versus
cognate control (Student's t-test); n=5.
Fig. 1. Glucose promoted a dose-dependent increase in LOOH formation over mannitol
in DLPC membranes. Membranes underwent autoxidation while incubated in a
phosphate buffer solution containing 5, 10 or 50 mM glucose or mannitol at 37 °C for
48 h. Total levels of LOOH were measured by the CHOD-iodide assay and percent
increase was calculated by normalizing to untreated control. ⁎pb0.01 versus control
(Dunnett multiple comparisons test; overall ANOVA pb0.0001; F=183.86); †pb0.0001
glucose versus equivalent mannitol concentration (Student's t-test); n=5.
1400 Y. Self-Medlin et al. / Biochimica et Biophysica Acta 1788 (2009) 1398–1403ﬁcant relationship between C/P ratios after the 48 h timepoint (data
not shown); however, the addition of glucose accelerated LOOH
formation and accentuated the cholesterol-dependent effect within
48 h (Fig. 2).
3.2. Membrane structural effects of glucose
Progressive lipid peroxidation has been shown to irreversibly alter
the structure of biological membranes by promoting cholesterol
crystalline domains and the eventual degradation of the overall
phospholipid bilayer structure [15]. We measured the effect of a
10 mM glucose (the physiological equivalent of high postprandial
blood sugar levels) or mannitol solution on model membrane
phospholipid structure using SAXS. The diffraction data were
correlated with lipid hydroperoxide values using the CHOD-iodide
assay of the same samples. Immediately following preparation of
membrane samples, prior to exposure to autoxidative conditions, no
signiﬁcant differences in membrane structure were observed for
untreated, mannitol- or glucose-treated membranes (Fig. 3). The
average membrane periodicity (d-space) was approximately 53 Å for
control, mannitol- and glucose-treated samples and no cholesterol
domains were detected. However, cholesterol domains were detected
as early as 24 h in the glucose-treated samples (data not shown). The
control and mannitol-treated samples did not begin to show these
membrane changes until 48 h with no or little reduction in bilayer
width. In contrast, by 48 h, the X-ray diffraction data of the glucose-
treated samples showed signs of advanced membrane degradation,
evidenced by a decrease in d-space to 49 Å, the presence of large
cholesterol domain peaks and the loss of higher order phospholipid
peaks (Fig. 3). These structural changes correlated with a two-fold
increase in lipid hydroperoxide levels in the glucose-treated samples
versus the mannitol-treated or untreated control samples.
3.3. Amlodipine/atorvastatin metabolite combination inhibits
hyperglycemic lipid peroxidation in MLVs
Treatment of DLPC model membranes at 0.6 C/P with AML and
ATM signiﬁcantly attenuated the effects of 50 mM glucose (Fig. 4).
LOOH formation was dramatically reduced by the combination
treatment in a dose-dependent manner over a range of concentra-
tions that correspond to pharmacologic doses (0.5 to 2.0 μM). Inaddition to their potent antioxidant effects, both of these drugs
have physicochemical properties that allow them to partition into
the membrane at the lipid/water interface [21]. These properties
diminish glucose oxidative damage by scavenging the lipid hydro-
peroxide radicals before they can propagate and disrupt the mem-
brane bilayer structure.
4. Discussion
It is generally accepted that there may be several reaction mecha-
nisms responsible for the various glycoxidation and lipoxidation
products resulting from the reaction of saccharides with proteins or
lipids [4,6]. Past studies typically focused on the chemistry involving
sugar-amine adducts and their downstream damage but this study
investigated the direct physical and chemical effects of glucose on the
oxidation of PUFA membranes with high cholesterol content. The
results of this study demonstrate that glucose autoxidation accele-
rated lipid peroxidation and the subsequent oxidative changes in
membrane structure and organization. Glucose, a reducing saccharide,
is susceptible to reaction at its anomeric carbonwith singlet oxygen or
other radical initiators [22]. This redox reaction can produce a glucose
radical or other reactive oxygen species (ROS), generating a pro-
oxidant effect in the lipid membrane. To conﬁrm this hypothesis, we
compared glucose to mannitol, which is structurally similar and
commonly used as an osmotic control in physiologic studies [20]. We
showed that glucosewas farmore reactive thanmannitol in producing
lipid hydroperoxides and inducing cholesterol crystalline domain
formation in DLPC membranes. The similar diffraction proﬁles, d-
space values and electron density proﬁles (not shown) obtained for
control, mannitol- and glucose-treated samples at 0 h indicate that
these disparate effects were not due to differences in hydration or
other membrane structural perturbations.
The high cholesterol levels used in our study also contributed to
physical alterations of the membrane structure, allowing more
efﬁcient radical penetration and propagation through the bilayer.
Speciﬁcally, the highly planar steroid nucleus of cholesterol reduces
the intermolecular distance between adjacent PUFA chains of the
lipids, thereby facilitating the rapid movement of free radicals
among the acyl chains [15]. This effect is veriﬁed by the cholesterol-
dependent increase in LOOH formation, which was enhanced by
glucose treatment. The correlation of cholesterol domain formation
with increased lipid hydroperoxide generation shown in our study
Fig. 3.Membrane lipid peroxidation and cholesterol domain formation increased with glucose treatment following 48 h of autoxidation. Small angle X-ray diffraction patterns were
obtained from oriented DLPC membranes (prepared at 0.6 C/P) in the absence (A) or presence of mannitol (C) or glucose (E) at 0 h peroxidation. All three samples exhibited a single
lipid phase with a d-space value of 53 Å. After 48 h exposure to lipid peroxidation, small cholesterol domain peaks (labeled 1′ and 2′) were observed in control (B) and mannitol-
treated (D) samples. In contrast, large cholesterol domain peaks and a decrease in bilayer d-space (49 Å) were observed for membrane samples treated with glucose and exposed to
oxidation for 48 h (F). Glucose and mannitol were tested at 10 mM in this X-ray diffraction experiment.
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may be linked to cholesterol crystal development, a hallmark
feature of atherosclerotic plaque. The observed progressive forma-
tion of cholesterol crystalline domains was accompanied by a
reduction in the membrane bilayer width. The reduction in width is
caused by the depletion of cholesterol from within the phospholipid
region into crystalline domains in addition to the physical changes
of the phospholipid acyl chains caused by oxidative damage.Evidence suggests that even minor physical changes in the cell
membrane may lead to the disruption of caveolae, cholesterol rich
membrane domains critical to many cellular processes, leading to
eNOS and insulin receptor dysfunction [12,23].
Glucose-mediated oxidative stress also contributes to the inﬂam-
matory pathways associated with diabetes and atherosclerosis
pathophysiology [24]. Speciﬁcally, oxidative stress contributes to
insulin resistance through an “oxidative-inﬂammatory cascade (OIC)”
Fig. 4. Atorvastatin metabolite and amlodipine inhibited glucose oxidative effect on
lipid peroxidation. DLPC membranes at 0.6 C/P were incubated with 50 mM glucose at
equimolar concentrations of atorvastatin metabolite and amlodipine and underwent
lipid peroxidation at 37 °C for 48 h. LOOH concentration was measured by the CHOD-
iodide assay. ⁎pb0.01 versus control without drug (Dunnett multiple comparisons test;
overall ANOVA pb0.0001; F=70.45); n=5.
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oxidant defense mechanisms while activating inﬂammatory respon-
ses from transcription factors and kinases, such as c-Jun N-terminal
kinase (JNK), protein kinase C (PKC) and inhibitor of kappa B kinase-
β (IKKβ) [25,26]. Some inﬂammatory pathways, such as activation of
IKKβ, have a causative role in the deleterious effects of high glucose
on endothelial cell function [27]. Nonacetylated salicylates have been
shown to block the transcription factor nuclear factor-κB (NF-κB)
activity through direct inhibition of IKKβ [26,27]. A recent double-
masked, placebo controlled study of 20 obese young adults found
that salsalate, a dimer of salicylic acid, reduced glycemia while
improving inﬂammatory cardiovascular risk indexes [28]. Studies
with drugs possessing antioxidant activity at the cellular level, either
directly or through causation, such as statins, glitazones, and
angiotensin converting enzyme (ACE) inhibitors, also have shown
beneﬁt in improving insulin resistance, the OIC mechanism, and in
some cases, glycemia [24,25].
Our results augment studies linking hyperglycemia and dyslipi-
demia to mechanisms of protein and lipid damage, LDL oxidation,
eNOS dysfunction and inﬂammation [4,5,29]. Glycation reactions
produce a cascade of imbalances disrupting normal metabolic, enzy-
matic and signaling pathways, which exacerbate the inﬂammation
and vascular damage from oxidative stress and may increase insulin
resistance [4,12]. Even acute periods of high glucose levels have been
shown to increase oxidative damage after ischemic stroke and cardiac
events [30,31]. While the current study did not utilize metal catalysts
commonly associated with glucose autoxidation, such as copper or
iron, the prevalence of these catalysts in the body may accelerate the
effects seen here [5]. For these reasons, therapeutic interventions of
metabolic disorders and cardiovascular risks should not only treat
hypertension and high cholesterol but should also increase antiox-
idants and control blood sugar levels. Laboratory studies have
demonstrated that, in addition to its powerful cholesterol lowering
effects, ATM is also a potent antioxidant [32] and the combination of
AML/ATM exhibits a synergistic antioxidant effect [21,33]. This study
conﬁrms that free radical-scavenging antioxidants, such as ATM, slow
the progression of oxidative damage in lipid membranes even under
conditions of model hyperglycemia and hyperlipidemia. The results
reported here also support clinical studies showing that the syner-
gistic beneﬁt of the AML/ATM combination reduces cardiovascular
events in patients that have various risk factors, including diabetes, as
compared to other combinations [34,35].Despite decades of research on the role of oxidative stress in the
progression of diabetes, metabolic disorders, and cardiovascular
disease, there is still considerable debate over the initial cause and
underlying mechanisms which lead to the progression of these
diseases. The results of our ﬁndings suggest that elevated reactive
saccharide levels in conjunction with elevated cholesterol levels may
contribute to these oxidative stress-induced disorders. Further
investigation on the effect of hyperglycemia on lipid vesicle compo-
sition and size, modeling the various types of particles and
membrane bilayers in vivo, may provide additional insight into the
mechanisms of these pathologies.
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